Teva’s bold pivot from generics to innovation is sending shockwaves through Wall Street, with every analyst giving it a buy and projecting 28% to 60% upside. Under CEO Richard Francis, the company’s flagship drug Austedo is soaring 41% and on track for $2B in sales, while Ajovy and Uzedy also deliver double-digit growth. Teva’s long-term strategy aims for 30% operating margins by 2027 — up from 12.5% — and includes a $700M acquisition of Emalex Biosciences to bolster future treatments. With its stock trading at a low valuation relative to earnings and new drugs like ecopipam on the horizon, the market is clearly pricing in Teva’s transformation — and investors are responding.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
